Cancer incidence in North West Algeria (Mascara) 2000-2010 by Benarba, Bachir et al.
EXCLI Journal 2014;13:709-723 – ISSN 1611-2156 
Received: April 16, 2014, accepted: June 03, 2014, published: June 23, 2014 
 
 
709 
Original article: 
CANCER INCIDENCE IN NORTH WEST ALGERIA (MASCARA) 2000-2010: 
RESULTS FROM A POPULATION-BASED CANCER REGISTRY 
 
Bachir Benarba*1,2, Boumedienne Meddah2, Houria Hamdani3 
 
1 Laboratoire de Bioconversion, Génie Microbiologie et Sécurité Sanitaire, Department of 
Biology, Faculty of Nature and Life Sciences, University of Mascara, Algeria 
2 Laboratory for Research on Biological Systems and Geomatics, Faculty of Nature and Life 
Sciences, University of Mascara, Algeria 
3 Cancer Registry of Mascara, Department of Epidemiology and Preventive Medicine, Health 
and Population Administration of Mascara, Algeria 
 
* Corresponding author: Bachir Benarba, Faculty of Nature and Life Sciences, University of 
Mascara, Algeria. E-mail: bachirsb@yahoo.fr. Tel: 213 7 95 12 32 88 
 
ABSTRACT 
Cancer is a leading cause of death worldwide accounting for 7.4 million deaths. Cancer has 
become a major public health concern in Algeria. The aim of the present study was to esti-
mate cancer incidence in Mascara Province based on the population-based cancer registry. 
We analyzed data from the cancer registry of Mascara covering all cancer cases diagnosed by 
all methods and included in the registry from 1st January 2000 to 31st December 2010. The re-
sults are presented as incidence rates of cases by site, sex, age, and crude rate. Age-
standardized rates per 100,000 person-years (ASRs) were calculated, using the direct method 
of standardization to the world population. 
A total of 1875 cases of invasive cancer were recorded. The mean age of diagnosis for all 
cancers was 52.66 ± 0.5 in men and 59.18 ± 0.6 in women. The ASR for all cancers in fe-
males was 27.8 per 100,000, and that for males was 23.6 per 100,000. The most important 
finding of the present study was the high incidence of liver cancer among males and females 
in Mascara. Among females, breast cancer was the most frequently reported followed by Cer-
vix uteri, liver and colon. The most frequent cancer types in males were lung, colon, esopha-
gus and stomach and liver.  
Cancer incidence in Mascara province was lower than that reported in other national and re-
gional registries. Findings of the present study revealed high incidence of liver cancer in the 
province, the highest in Algeria, suggesting high prevalence of risk factors. 
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INTRODUCTION 
Algeria is a big northern African country, 
more than five times the size of California. It 
is the largest country of the Mediterranean 
Sea, the largest on the African continent and 
the tenth-largest country in the world in 
terms of land area. It is limited by the Medi-
terranean Sea in the north and by the Sahara 
in the south. Since the 1970s, the country 
exhibited the typical characteristics of a de-
veloping nation with a rapidly growing 
economy (Bendjoudi et al., 2009). Since the 
1980s, Algeria has entered an epidemiologi-
cal transition characterized by a reduction in 
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endemic communicable diseases and the ap-
pearance of new pathologies, particularly 
those linked to increased life expectancy 
such as cancer (AfDB, 2006). 
Cancer is a leading cause of death world-
wide accounting for 7.4 million deaths 
(around 13 % of all deaths) in 2004. The fu-
ture burden of cancer in the developing 
world is likely to be exasperated by the ex-
pected increases in life expectancy and aging 
and growth of the population (Jemal et al., 
2010). According to the GLOBOCAN 2008, 
the age-standardized incidence and mortality 
rates of cancer in Algeria were 105.8 and 
80.3/100,000, respectively. It is projected 
that by 2015, the number of new cancer cas-
es will increase by 24 %, from 28736 in 
2008 to 35628 (Ferlay et al., 2010).  
Population-based cancer registries collect 
the data on cancer new cases and deaths 
from covered population to describe and sur-
veil the cancer incidence, mortality and sur-
vival (Chen et al., 2012). Among the primary 
goals of cancer registries is the reduction of 
cancer-related morbidity and mortality 
through the facilitation of cancer research 
and the education of scientists, clinicians, 
and the public (McLaughlin et al., 2010). 
Cancer registries have been widely used in 
epidemiological research. They are an essen-
tial component of a fully developed cancer-
control program. In addition to providing in-
formation on current and future needs for 
services, they are used to monitor programs 
of prevention, early detection and cure 
(treatment) (Parkin, 2006). To assess cancer 
epidemiology in Algeria, cancer registers 
were established in the 1980s in various 
parts of the country. These registers enabled 
the most prevalent cancers in both men and 
women to be recorded and a certain number 
of anti-cancer actions to be undertaken 
(Abid, 2009). The Mascara Population-based 
Cancer Registry was established in 1999, 
and has been a member of the International 
Association of Cancer Registries (IACR) 
since 2010. 
MATERIALS AND METHODS 
Mascara province (5941 km²) is located 
in the north west of Algeria, (at 360 km of 
Algiers) with mediterranean climate and 
mean annual precipitations of about 450 mm. 
In 2010, the total population was 826334, 
with male/female ratio of about 1.04. The 
population pyramid of Mascara is shown in 
Figure 1. 
Data were collected from the cancer reg-
istry of Mascara during the months of March 
and April 2013. We obtained the data of all 
cancer cases diagnosed by all methods and 
included in the registry from 1st January 
2000 to 31st December 2010 (n = 1875). 
The registry is run by the Department of 
Epidemiology and is supervised by the 
health and population administration of Mas-
cara. Anatomical sites of cancers are coded 
according to the 10th edition of international 
classification of diseases adopted by WHO 
in 2002 (ICD-10). World Health Organiza-
tion cancer registry software version 4 (Can 
Reg4) is used to enter, clean and analyze da-
ta. The software had ability to detect dupli-
cates thereby reducing the risk of double 
counting of cases that might have visited 
several hospitals or same hospital at different 
times. It also had the ability to estimate the 
age-standardized incidence rates (Msyambo-
za et al., 2012). 
The results are presented as incidence ra-
tes of cases by site, sex, age, and crude rate. 
For comparison with data from other regis-
tries, age-standardized rates per 100,000 per-
son-years (ASRs) were calculated, using the 
direct method of standardization to the world 
population. 
 
Figure 1: Population pyramid of Mascara (2010) 
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RESULTS 
During the 10 years (2000-2010) period 
of the present study, we recorded a total of 
1875 cases of invasive cancer. Of the total 
patients 1024 (54.6 %) were males and 851 
(45.4 %) were females, the sex ratio was 
1:0.8. The mean age of diagnosis for all can-
cers was 52.66 ± 0.5 in men and 59.18 ± 0.6 
in women.  
The diagnosis of cancer was based on ra-
diology in 25 %, histology of primary in 
24 %, clinical in 23 %, histology of metasta-
ses in 10 %, cytology in 10 % and others in 
8 % of cases (Figure 2). 
Crude incidence rates for all cancers 
were overall higher for females than males 
(23.0 and 18.4 per 100,000, respectively). 
The ASR for all cancers in females was 27.8 
per 100,000, and that for males was 23.6 per 
100,000 (Tables 1 and 2). The childhood 
cancer incidence (0-14 years) was the same 
among boys (4 per 100,000) and girls (4 per 
100,000). As shown in Figure 3, ASRs for 
all cancers increased steadily from 0-4 years 
to 70-74 years. ASRs were lower in 0-29 
years age group and higher in 30-75+ years 
age group. The highest ASR (W) was found 
in the 70-74 years age group for both males 
and females. It was 169 per 100,000 for 
males and 157 per 100,000 for females.  
 
 
Figure 2: Common basis of diagnosis 
   
Figure 3: Age standardized rates for all cancers in men and women including (A) and excluding (B) 
NMSC for the period 2000–2010 in Mascara 
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Table 1: Percent distribution of cancer cases by site, age-specific incidence rates per 100,000, crude and age standardized rates (ASR) adjusted to the World 
Standard Population (W) among males in Mascara (2000-2010) 
Site (CIM-10) n % 
Age-specific rates Crude 
rate 
ASR 
(W) Age  
unknown 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ 
Lip(C00) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.2 0.0 0.1 
Tongue (C01-C02) 6 0.7 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.5 0.0 1.0 1.1 1.4 1.2 0.1 0.2 
Mouth (C03-C06) 14 1.6 0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.5 1.1 2.0 1.0 1.1 1.4 3.6 0.3 0.4 
Salivary glands (C07-
C08) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 
Tonsil (C09) 3 0.4 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 
Other oropharynx 
(C10) 11 1.3 0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 1.6 0.0 2.0 1.1 0.0 2.4 0.2 0.3 
Nasopharynx (C11) 27 3.2 0 0.0 0.0 0.0 0.2 0.6 0.6 0.5 0.6 0.7 0.9 1.1 0.7 3.0 2.1 4.3 1.2 0.6 0.7 
Hoppharynx (C12-C13) 3 0.4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.0 0.0 0.0 1.2 0.1 0.1 
Pharynx unspecified 
(C14) 18 2.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 1.4 0.5 2.0 3.0 2.1 2.8 2.4 0.4 0.5 
oesophagus (C15) 16 1.9 0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.5 0.5 0.7 3.0 3.2 1.4 3.6 0.3 0.4 
Stomach (C16) 65 7.6 0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.4 4.1 7.9 4.6 3.9 9.6 8.5 14.6 1.4 1.8 
Small intestine (C17) 4 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.5 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 
Colon (C18) 44 5.2 0 0.0 0.0 0.0 0.4 0.0 0.4 0.5 0.6 0.0 3.2 2.1 3.3 5.9 5.3 8.5 3.6 0.9 1.2 
Rectum (C19-C20) 38 4.5 1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 1.5 1.4 3.2 1.3 4.9 3.2 7.1 4.9 0.8 1.0 
Anus (C21) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Liver (C22) 48 5.6 0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.2 0.4 1.4 1.1 2.7 10.8 5.3 14.2 7.3 1.0 1.4 
Gallbladder etc. (C23-
C24) 26 3.1 0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 2.1 1.3 3.9 6.4 4.3 4.9 0.6 0.8 
Pancreas (C25) 27 3.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 1.6 4.6 4.9 2.1 5.7 2.4 0.6 0.8 
Nose, sinuses etc. 
(C30-C31) 3 0.4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 1.4 0.0 0.1 0.1 
Larynx (C32) 14 1.6 0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.5 0.5 2.0 2.0 1.1 5.7 0.0 0.3 0.4 
Trachea, Bronchus, 
Lung (C33-C34) 169 19.9 0 0.2 0.0 0.0 0.0 0.0 0.2 0 .0 1.2 1.8 3.2 10.0 17.9 29.6 25.6 42.6 25.5 3.6 4.9 
Other Thoracic organs 
(C37-C38) 5 0.6 0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.0 2.1 0.0 0.0 0.1 0.1 
Bone (C40-C41) 18 2.1 0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.3 0.4 0.5 2.1 1.3 3.0 0.0 2.8 2.4 0.4 0.5 
Melanoma of skin 
(C43) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 0.1 
Other skin (C44) 12 1.4 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.3 2.0 0.0 5.7 2.4 0.3 0.3 
Mesothelioma (C45) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.1 0 .0 0.0 0.0 0.1 
Kaposi sarcoma (C46) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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Table 1 (cont.): Percent distribution of cancer cases by site, age-specific incidence rates per 100,000, crude and age standardized rates (ASR) adjusted to 
the World Standard Population (W) among males in Mascara (2000-2010) 
Site (CIM-10) n % 
Age-specific rates Crude 
rate 
ASR 
(W) Age  
unknown 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ 
Connective and soft tis-
sue (C47-C49) 4 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.5 0.7 1.0 0.0 0.0 0.0 0.1 0.1 
Breast (C50) 6 0.7 0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.5 0.7 0.0 1.1 0.0 0.0 0.1 0.2 
Penis (C60) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 
Prostate (C61) 54 6.3 0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.4 0.0 0.5 1.3 6.9 3.2 14.2 34.0 1.2 1.5 
Testis (C62) 4 0.5 0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 
Other male genital (C63) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 
Kidney (C64) 11 1.3 1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.7 0.0 2.1 2.8 0.0 0.2 0.2 0.3 
Renal Pelvis (C65) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ureter (C66) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Bladder (C67) 51 6 3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.5 2.1 3.3 5.9 6.4 18.5 13.3 1.1 1.5 
Other Urinary organs 
(C68) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Eye (C69) 6 0.7 1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 2.1 0.0 0.0 0.1 0.2 
Brain, Nervous system 
(C70-C72) 19 2.2 1 0.0 0.3 0.5 0.0 0.4 0.2 0.3 0.9 0.0 0.5 1.1 1.3 0.0 3.2 0.0 0.0 0.4 0.4 
Thyroid (C73) 5 0.6 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.0 1.1 1.4 0.0 0.1 0.2 
Adrenal gland (C74) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other Endocrine (C75) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Hodgkin disease (C81) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 
Non-Hodgkin lymphoma 
(C82-C85 ; C96) 19 2.2 1 0.0 0.3 0.0 0.0 0.2 0.2 0.0 0.9 0.0 0.5 2.1 0.0 1.0 4.3 1.4 1.2 0.4 0.5 
Immunoproliferative dis-
ease (C88) 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Multiple Myeloma (C90) 4 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.5 0.0 0.0 0.0 0.0 1.2 0.1 0.1 
Lymphoid Leukaemia 
(C91) 4 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 1.1 1.4 1.2 0.1 0.1 
Myeloid Leukaemia (C92-
C94) 3 0.4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.0 1.1 0.0 0.0 0.1 0.1 
Leukaemia, cell unspeci-
fied (C95) 1 0.1 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other & unspecified 75 8.8 0 0.0 0.8 0.2 0.7 0.6 0.2 1.3 0.9 2.2 1.8 4.7 4.6 5.9 6.4 9.9 13.3 1.6 1.9 
                      
All sites Total 851  11 1 2 1 3 2 3 5 9 12 26 51 64 109 108 169 150 18.4 23.6 
All sites but C44 839  10 1 2 1 3 2 3 5 9 12 26 50 62 107 108 163 148 18.1 23.2 
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Table 2: Percent distribution of cancer cases by site, age-specific incidence rates per 100,000, crude and age standardized rates (ASR) adjusted to the World 
Standard Population (W) among females in Mascara (2000-2010) 
Site (CIM-10) n % 
Age-specific rate Crude 
rate 
ASR 
(W) Age  
unknown 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ 
Lip(C00) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 
Tongue (C01-C02) 3 0.3 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.1 1.1 0.1 0.1 
Mouth (C03-C06) 3 0.3 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 2.1 0.0 0.1 0.1 
Salivary glands (C07-C08) 3 0.3 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.1 0.1 
Tonsil (C09) 3 0.3 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 
Other oropharynx (C10) 3 0.3 0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 
Nasopharynx (C11) 10 1.0 0 0.0 0.0 0.2 0.7 0.2 0.0 0.3 0.3 0.8 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.2 
Hoppharynx (C12-C13) 2 0.2 0 0.0 0.3 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 
Pharynx unspecified 
(C14) 4 0.4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.1 0.1 0.1 
oesophagus (C15) 5 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.0 1.1 0.0 2.1 0.1 0.1 
Stomach (C16) 50 4.9 0 0.0 0.0 0.0 0.0 0.2 0.4 1.3 0.3 1.1 1.9 4.4 1.4 7.9 5.5 6.3 8.4 1.1 1.4 
Small intestine (C17) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Colon (C18) 35 3.4 0 0.0 0.0 0.2 0.0 0.4 0.0 0.5 0.0 1.5 1.9 3.3 2.8 2.0 6.7 4.2 2.1 0.8 1.0 
Rectum (C19-C20) 45 4.4 0 0.0 0.0 0.0 0.0 0.2 0.7 0.5 0.9 1.5 2.3 2.2 2.8 3.0 4.4 14.6 5.3 1.0 1.3 
Anus (C21) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 
Liver (C22) 44 4.3 0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.8 2.3 4.4 2.8 4.9 6.7 6.3 8.4 1.0 1.3 
Gallbladder etc. (C23-
C24) 49 4.8 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.5 2.3 5.0 2.1 10.8 8.9 8.4 3.2 1.1 1.5 
Pancreas (C25) 20 2.0 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 2.2 2.1 5.9 1.1 6.3 1.1 0.4 0.7 
Nose, sinuses etc. (C30-
C31) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 
Larynx (C32) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.0 0.1 
Trachea, Bronchus, Lung 
(C33-C34) 29 2.8 0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.6 0.8 0.9 0.6 1.4 4.9 3.3 10.4 5.3 0.7 0.9 
Other Thoracic organs 
(C37-C38) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Bone (C40-C41) 18 1.8 0 0.0 0.3 0.2 0.2 0.8 0.0 0.0 0.3 0.4 0.9 0.0 1.4 1.0 0.0 2.1 3.2 0.4 0.4 
Melanoma of skin (C43) 1 0.1 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other skin (C44) 27 2.6 1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 2.3 1.4 2.2 0.7 2.0 1.1 4.2 4.2 0.6 0.7 
Mesothelioma (C45) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Kaposi sarcoma C46) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 
Connective and soft tis-
sue (C47-C49) 6 0.6 0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.4 0.0 0.0 0.7 1.0 1.1 0.0 0.0 0.1 0.2 
Breast (C50) 374 36.5 3 0.0 0.3 0.2 0.2 0.0 1.6 8.9 14.5 26.7 29.0 22.6 19.6 21.7 28.9 39.7 13.7 8.4 9.7 
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Table 2 (cont.): Percent distribution of cancer cases by site, age-specific incidence rates per 100,000, crude and age standardized rates (ASR) adjusted to 
the World Standard Population (W) among females in Mascara (2000-2010) 
Site (CIM-10) n % 
Age-specific rate Crude 
rate 
ASR 
(W) Age  
unknown 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ 
Vulva (C51) 5 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 1.0 0.0 2.1 2.1 0.1 0.2 
Vagina (C52) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 
Cervix uteri (C53) 108 10.5 1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.6 5.6 8.4 10.5 14 .0 7.9 8.9 14.6 5.3 2.4 3.1 
Corpus uteri (C54) 5 0.5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.7 0.0 0.0 2.1 0.0 0.1 0.2 
Uterus unspecified (C55) 17 1.7 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.5 2.2 2.8 1.0 2.2 2.1 2.1 0.4 0.5 
Ovary (C56) 25 2.4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.1 1.4 2.8 2.8 2.0 4.4 0.0 1.1 0.6 0.7 
Other Female Genital (C57) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Placenta (C58) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Kidney (C64) 8 0.8 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 1.4 0.0 0.0 1.0 0.0 2.1 1.1 0.2 0.2 
Renal Pelvis (C65) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ureter (C66) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Bladder (C67) 12 1.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.5 0.6 0.0 2.0 2.2 2.1 2.1 0.3 0.4 
Other Urinary organs (C68) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Eye (C69) 2 0.2 0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 
Brain, Nervous system 
(C70-C72) 13 1.3 0 0.0 0.3 0.0 0.2 0.2 0.2 0.0 0.0 0.8 0.0 0.6 1.4 1.0 0.0 2.1 2.1 0.3 0.3 
Thyroid (C73) 7 0.7 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.0 1.0 0.0 2.1 0.0 0.2 0.2 
Adrenal gland (C74) 1 0.1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other Endocrine (C75) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Hodgkin disease (C81) 6 0.6 0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.6 0.0 0.5 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 
Non-Hodgkin lymphoma  
(C82-C85 ; C96) 8 0.8 0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.5 0.6 0.7 0.0 0.0 2.1 1.1 0.2 0.2 
Immunoproliferative dis-
ease (C88) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Multiple Myeloma (C90) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Lymphoid Leukaemia (C91) 2 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 1.1 0.0 0.1 
Myeloid Leukaemia (C92-
C94) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Leukaemia, cell unspeci-
fied (C95) 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other & unspecified 61 0.6 0 0.9 0.0 0.7 0.2 0.4 0.9 1.9 1.6 1.1 1.4 2.2 1.4 1.0 6.7 16.7 8.4 1.4 1.6 
   0                   
All sites Total 1024  9 1 1 2 2 3 5 17 23 50 59 72 64 86 97 157 90 23.0 27.8 
All sites but C44 997  8 1 1 2 2 3 5 17 23 48 58 70 63 84 95 153 86 22.4 27.1 
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Among females, breast cancer was the 
most frequently reported (36.5 %), followed 
by Cervix uteri (10.5 %), liver (9.1 %) and 
colon (7.8 %) (Table 3). The most frequent 
cancer types in males were lung (19.9 %), 
colon (9.7 %), esophagus and stomach 
(9.5 %) and liver (8.7 %) (Table 4). 
 
DISCUSSION 
Algeria has been the only country in 
North Africa in which the burden of cancer 
has been measured quite regularly for 20 
years (Zanetti et al., 2010). The present study 
is based on the cancer registry of Mascara 
(North West of Algeria) created in 1999. 
 
Table 3: Percent distribution of the 7 most com-
mon cancers by site, frequency (n), percentage, 
crude and age standardized rates (ASR) adjust-
ed to the World Standard Population (W) among 
females 
Rank Site n % Crude rate 
ASR 
(W) 
1 Breast 374 36.5 8.4 9.7 
2 Cervix 108 10.5 2.4 3.1 
3 Liver 93 9.1 2.1 2.8 
4 Colon 80 7.8 1.8 2.3 
5 Stomach 50 4.9 1.1 1.4 
6 Lung 29 2.8 0.7 0.9 
7 Ovary 25 2.4 0.6 0.7 
 
Table 4: Percent distribution of the 7 most com-
mon cancers by site, frequency (n), percentage, 
crude and age standardized rates (ASR) adjust-
ed to the World Standard Population (W) among 
males 
Rank Site n % Crude rate 
ASR 
(W) 
1 Lung 196 19.9 3.6 4.9 
2 Colon 82 9.7 1.7 2.2 
3 Liver 74 8.7 1.6 2.2 
4 Stomach 65 7.6 1.4 1.8 
5 Pharynx 59 7 1.3 1.6 
6 Prostate 54 6.3 1.2 1.5 
7 Bladder 51 6 1.1 1.5 
The registry covers an area of 5941 km², and 
caters to a population of about 826334. To 
our knowledge there is no previous study 
about the incidence or pattern of cancer in 
Mascara. The most interesting feature among 
our results is the low incidence of cancer. 
We found an overall ASR for all cancers in 
females of 27.8 per 100,000, and that for 
males of 23.6 per 100,000. These rates are 
lower than national ASR of 104.9 and 108.7, 
respectively (Ferlay et al., 2010). Interesting-
ly, cancer incidence in Mascara was lower 
than that reported in other regions in Algeria 
and North Africa (Table 5a and b). These 
differences could be due to geographic 
and/or ethnic factors (Masoompour et al., 
2011) and low prevalence of risk factors, as 
Mascara is a rural region located in internal 
west of Algeria. Distribution of many can-
cers within developed and developing coun-
tries shows a lower incidence in rural than in 
urban areas (Hislop et al., 1986; Hall et al., 
2005; Hammouda et al., 2007; Swaminathan 
et al., 2009; Dey et al, 2011). 
The most important finding of the pre-
sent study was the high incidence of liver 
cancer among males and females in Mascara, 
2.2 and 2.8/100,000, respectively. It was 
nine-fold higher than that in females in Oran 
(0.3/100,000) (Mokhtari et al., 2007), nearly 
five-fold higher than that in females in Batna 
(Bouhidel et al., 2006) and Casablanca (0.6/ 
100,000) (Benider et al., 2012). Among 
males, the incidence was eleven-fold higher 
than that in Batna (0.2/100,000), similar to 
that observed in Algiers (2.42/100,000) and 
lower than that in Benghazi and Aswan (El 
Mistiri et al., 2004; Ibrahim, 2010). This 
may be due to high prevalence of risk factors 
such as chronic hepatitis B viral infection, 
and exposure to aflatoxin in food (Moham-
mad et al., 2009) or pollution due to insecti-
cides (Salim et al., 2009). Indeed, HBV inci-
dence in Mascara is 1.5-fold higher than that 
in all Algeria (7.16 vs 4.76/100,000) (INSP, 
2007). Hepatitis B virus (HBV) is considered 
to be one of the most important causes of 
chronic hepatitis, cirrhosis and hepatocellu-
lar carcinoma (HCC) (Gasim, 2013). Patients 
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with chronic HBV infection have a 15–25 % 
risk of dying prematurely from HBV-related 
cirrhosis or HCC (Mihigo et al., 2013). It has 
been reported that 48 % of HCC and 44 % of 
cirrhosis were attributable to HBV infection 
in African countries such as Algeria (Perz et 
al., 2006).  
 
Table 5a: Age-standardized incidence rates directly adjusted to the World Standard Population per 
100,000 for top the most common cancers in Mascara among males compared to those in selected 
northern African registries 
 All sites Lung Colon Stomach Liver Pharynx Prostate Bladder
A
lg
er
ia
 
Mascara 
(present study) 23.6 4.9 2.2 1.8 2.2 1.6 1.5 1.5 
Algeria 
(2008) 
(Ferlay et al., 
2010) 
108.7 19.4 10.6 7.1 1.3 1.0 7.1 11.9 
Algiers 
(2007) 
(Hammouda et 
al., 2007) 
148.0 23.07 8.17 10.22 2.42 0.05 13.57 12.53 
Oran (2006) 
(Mokhtari and 
Ammour, 2007) 
44.3 6.8 2.1 3.3 1.4 0.0 1.1 4.9 
Batna(2006) 
(Bouhidel et al., 
2006) 
65.4 9.7 4.5 4.7 0.2 0.2 3.6 5.2 
M
or
ro
co
 Grand  
Casablanca 
(2005-2007) 
(Benider et al., 
2012) 
120.7 25.9 4.7 4.8 0.7 0.0 13.5 8.7 
Tu
ni
si
a Nord Tunisie 
(2004-2006) 
(Benabdelah 
and Hizem Ben-
ayoub, 2004) 
136.2 32.5 7.1 6.1 1.8 0.1 11.8 13.7 
Li
by
a Benghazi 
(2004) 
(El Mistiri et al., 
2004) 
129.5 26.66 8.75 4.46 4.88 0.3 9.8 12.64 
Eg
yp
t Aswan 
(2008) 
(Ibrahim et al., 
2010) 
142.5 11.2 3.9 4.1 17.4 0.3 9.2 18.6 
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Table 5b: Age-standardized incidence rates directly adjusted to the World Standard Population per 
100,000 for top the most common cancers in Mascara among females compared to those in selected 
northern African registries 
 All sites Breast Cervix Liver Colon 
Esophagus 
and stomach Lung Ovary 
A
lg
er
ia
 
Mascara 
(present study) 27.8 9.7 3.1 2.8 2.3 1.4 0.9 0.7 
Algeria 
(2008) 
(Ferlay et al., 
2010) 
104.9 28.6 10.4 1.1 9.1 4.4 2.5 4.0 
Algiers 
(2007) 
(Hammouda et 
al., 2007) 
165.6 65.1 10.0 1.3 10.4 6.8 5.0 8.7 
Oran (2006) 
(Mokhtari and 
Ammour, 2007) 
82.7 34.7 15.1 0.3 1.6 1.7 1.5 1.9 
Batna(2006) 
(Bouhidel et al., 
2006) 
65.5 16.1 4.6 0.6 2.1 2.6 0.4 1.0 
M
or
ro
co
 Grand 
Casablanca 
(2005-2007) 
(Benider et al., 
2012) 
115.9 36.4 15.0 0.6 3.2 2.7 2.9 5.3 
Tu
ni
si
a Nord Tunisie 
(2004-2006) 
(Benabdelah 
and Hizem Ben-
ayoub, 2004) 
102.3 31.84 4.19 1.17 5.89 3.67 2.88 4.14 
Li
by
a Benghazi 
(2004) 
(El Mistiri et al., 
2004) 
104.26 23.27 3.48 2.53 8 .1 2.07 2.02 3.9 
Eg
yp
t Aswan 
(2008) 
(Ibrahim et al., 
2010) 
166.8 63.9 0.9 8.7 3.5 2.4 3.8 9.1 
 
The most important finding of the pre-
sent study was the high incidence of liver 
cancer among males and females in Mascara, 
2.2 and 2.8/ 100,000, respectively. It was 
nine-fold higher than that in females in Oran 
(0.3/ 100,000) (Mokhtari et al., 2007), nearly 
five-fold higher than that in females in Batna 
(Bouhidel et al., 2006) and Casablanca 
(0.6/100,000) (Benider et al., 2012). Among 
males, the incidence was eleven-fold higher 
than that in Batna (0.2/100,000), similar to 
that observed in Algiers (2.42/100,000) and 
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lower than that in Benghazi and Aswan (El 
Mistiri et al., 2004; Ibrahim, 2010). This 
may be due to high prevalence of risk factors 
such as chronic hepatitis B viral infection, 
and exposure to aflatoxin in food (Moham-
mad et al., 2009) or pollution due to insecti-
cides (Salim et al., 2009). Indeed, HBV inci-
dence in Mascara is 1.5-fold higher than that 
in all Algeria (7.16 vs 4.76/ 100,000) (INSP, 
2007). Hepatitis B virus (HBV) is considered 
to be one of the most important causes of 
chronic hepatitis, cirrhosis and hepatocellu-
lar carcinoma (HCC) (Gasim, 2013). Patients 
with chronic HBV infection have a 15–25 % 
risk of dying prematurely from HBV-related 
cirrhosis or HCC (Mihigo et al., 2013). It has 
been reported that 48 % of HCC and 44 % of 
cirrhosis were attributable to HBV infection 
in African countries such as Algeria (Perz et 
al., 2006).  
It is well documented that ingestion of 
foods contaminated with the mycotoxin, af-
latoxin is an important risk factor among 
people in developing countries, together with 
active hepatitis virus infection (WHO, 2003). 
Aflatoxins are important causal factors of 
liver cancer (Ferrante et al, 2012). In Alge-
ria, foods most susceptible to aflatoxin con-
tamination are locally produced or imported 
cereals such as wheat. Climatic conditions 
characterized by high humidity and tempera-
ture and inadequate storage practices con-
tribute to the potential for significant expo-
sure of the Algerian population to aflatoxins 
(Riba et al., 2010). It has been reported that 
25–40 % of cereals consumed in the world 
are contaminated by these compounds (Pit-
tet, 1998). Riba et al. (2008) revealed the wi-
despread occurrence of aflatoxigenic strains 
of Aspegillus flavus in Algeria. Aflatoxigenic 
Aspergillus (belonging to section Flavi and 
Nigri) were the major fungal species most 
commonly isolated from Algerian wheat. 
Recently, Gacem et al. (2011) demonstrated 
important contaminations of local and im-
ported wheat stored in west Algeria. The af-
latoxinogenic genus Aspergillus represented 
41 to over 86 % of the total flora. Further-
more, in Algeria about 400 pesticides are 
homologated, and more than 30000 tons of 
pesticides are used every year. The excessive 
and non rational use of these chemicals, with 
the absence of basic security measures 
makes of Algerians as the most exposed ones 
to be affected by pesticides (Slimani et al., 
2011).  
Regarding the most frequent cancers 
among males (Table 5a), lung cancer was the 
leading site followed by colon cancer. In Al-
geria, lung cancer has been reported to be the 
commonest cancer in males with an ASR of 
19.4/100,000 (Ferlay et al., 2011). As shown 
in Figure 4, the incidence of lung cancer in-
creases steadily with age, from the 40–49 
year age group to reach the highest ASR ob-
served in 70-74 year age group. Lung cancer 
has been closely linked to tobacco smoking 
(Binu et al., 2007). Around 85 - 90 % of lung 
cancer could be attributed to the use of to-
bacco directly or indirectly. In developing re-
gions, 53 % of cancer deaths are caused by 
smoking (Ezzati et al., 2005). The trend for 
incidence ASRs of lung cancer shows obvi-
ous correlation with the smoking frequency 
in most of the Arab countries such as Algeria 
(Salim et al., 2011). Male smoking preva-
lence in Algeria is 33.9 % (WHO, 2011). In 
Northern Africa, over 90 % of lung cancer 
cases in men are attributable to smoking, re-
vealing a smaller environmental contribution 
(< 2 % of incident cancers) (McCormack and 
Schüz, 2012). On other hand, cannabis 
smoking was found to be one of the im-
portant causes of lung cancer in men in Al-
geria (Berthiller et al, 2008). 
According to our results, breast cancer 
was the most common malignancy in fe-
males accounting for 36.9 % of the total fe-
male cancers in Mascara. Its incidence 
(9.6/100,000) is the lowest reported from any 
other Algerian and North African registries 
(Table 5b). In addition, cervix cancer ranked 
2nd among females with an ASR of 3.1/ 
100,000. These findings are comparable to 
the pattern found in other regions in Algeria 
(Ferlay et al., 2010) and in some Arab coun-
tries like Morroco (Benider et al., 2011) or 
Lebanon (Adib et al., 1998).  
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The low incidence of breast cancer in 
Mascara can be read in two different ways: 
first, these results may reflect the reality, 
possibly due to low prevalence of certain 
risk factors. Secondly, these results can be 
skewed by the fact that women do not have 
access to health care services and do not 
benefit from early diagnosis, or are support-
ed in a facility outside Mascara. Breast can-
cer development is a multifactorial process. 
This complex process is a result of biologic, 
environmental, genetic, hormonal, and life-
style factors (Gross, 2000).  
Factors that contribute to the increasing 
trends in breast cancer incidence are not fully 
understood, but thought to reflect lifestyle 
changes associated with westernization. The 
“Westernization” of Algerian population is 
due to delayed childbearing, lower parity, 
reduced breast-feeding, decreased exercise 
and dietary changes (Jalkh et al., 2012). 
 
 
Figure 4: Age specific incidence rates for lung, colon and stomach cancer in males for the period 
2000–2010 in Mascara 
 
 
Figure 5: Age specific incidence rates for breast, cervix and colon cancer in females for the period 
2000–2010 in Mascara 
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Although ASRs of breast cancer among 
females in Mascara increase with age to 
reach a peak up to 5th decade, ASRs increase 
to reach a second peak in 70-74 years age 
group (Figure 5). This is in sharp contrast to 
the current age pattern at diagnosis of breast 
cancer in low-risk countries characterized by 
an increase in the rate around menopause, 
and a decrease thereafter  (Rodriguez-Cuevas 
et al., 2001). The second peak in 70-74 years 
age group may be attributed to late presenta-
tion reflecting poor health seeking behavior 
(Oluwagbemiga et al., 2012). 
 
CONCLUSION  
Despite the fact that the present study 
covers ten years from 2000 to 2010, some 
limitations should be considered. An im-
portant limitation is the retrospective nature 
of the study. Another limitation is that the 
cancer registry was established only in 1999 
and no previous studies on cancer incidence 
in Mascara were available. Furthermore, un-
der-reporting may have underestimated the 
rate estimates. 
The present study is the first estimating 
cancer incidence in Mascara province. Can-
cer incidence was lower than that reported in 
other regions in Algeria and North Africa. 
Understanding this fact needs further inves-
tigations of geographic and/or ethnic charac-
teristics of the local population. The high in-
cidence of liver cancer in Mascara, the high-
est in Algeria, highlights an urgent need to 
examine prevalence of related risk factors 
such chronic hepatitis B viral infection. Re-
garding the most frequent cancers (lung 
among males and breast cancer among fe-
males), our results indicate the necessity of 
developing screening programs (aiming early 
detection) and better cancer prevention poli-
cy.  
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